文献速递肿瘤 PET/CT

食管鳞癌治疗前肿瘤SUR与MTV预后价值的验证

Confirmation of the prognostic value of pretherapeutic tumor SUR and MTV in patients with esophageal squamous cell carcinoma.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2019-04-04

本研究在147例新诊断食管鳞癌患者中,于根治性放化疗前进行18F-FDG PET/CT,验证肿瘤-血标准摄取值比(SUR)的预后价值。单因素分析显示MTV、TLG和SURmax为总生存(OS)的显著预后因素,SUVmax对任何终点均无预后价值。多因素分析中MTV是OS的独立预后因素,SURmax不是独立预测因子,提示在该患者群中治疗前MTV是PET基风险分层的首选参数。

要点

  • 治疗前MTV是食管鳞癌OS的独立预后因素,SURmax非独立预测因子。
  • SUR较SUV预后价值明显改善,但不能提供MTV之外的额外预后信息。
  • MTV和TLG是局部区域控制(LRC)的显著预后因素,SURmax仅呈趋势。

核心结论

  • 肿瘤SUR较SUV预后价值明显改善,验证了既往关于OS的发现。
  • SUR提供临床参数之外的预后信息,但不提供MTV之外的额外预后信息。
  • 治疗前MTV是该设定下PET基风险分层的首选参数,尚需进一步研究证实。

研究设计与样本

  • 147例连续新诊断食管鳞癌患者(115男,32女,平均年龄62岁)在根治性放化疗前接受18F-FDG PET/CT。
  • 原发肿瘤MTV用自适应阈值法勾画,计算SUVmax和TLG(MTV×SUVmean),血SUV通过低剂量CT手动勾画主动脉确定,SUR为肿瘤SUV与血SUV比值。
  • 行单因素Cox回归和Kaplan-Meier分析(OS、DM、LRC),并行包含临床相关参数的多因素Cox回归。

主要发现

  • 单因素Cox回归显示MTV、TLG和SURmax为OS的显著预后因素。
  • MTV和TLG为LRC的显著预后因素,SURmax仅呈显著趋势。
  • 无任何PET参数对DM有预后价值,SUVmax对任何研究终点均无预后价值。
  • 多因素分析(T分期、N分期、MTV、SURmax)中MTV是OS的独立预后因素,对LRC呈显著趋势,SURmax不是OS或LRC的独立预测因子。
  • 将PET参数分别纳入多因素分析时,MTV和SURmax均为OS的预后因素,MTV为LRC的独立预后因素。

临床怎么用

  • 在食管鳞癌根治性放化疗前,可优先采用治疗前MTV进行PET基风险分层。
  • SUR较SUV预后价值更优,但本研究中未显示其超越MTV的额外预后价值。

局限性

  • 原文未明确列出局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The prognosis for patients with inoperable esophageal carcinoma is still poor and the reliability of individual therapy outcome prediction based on clinical parameters is not convincing. In a recent publication, we were able to show that PET can provide independent prognostic information in such a patient group and that the tumor-to-blood standard uptake ratio (SUR) can improve the prognostic value of tracer uptake values. The present investigation addresses the question of whether the distinctly improved prognostic value of SUR can be confirmed in a similar patient group that was examined and treated at a different site. METHODS: 18F-FDG PET/CT was performed in 147 consecutive patients (115 male, 32 female, mean age: 62 years) with newly diagnosed esophageal squamous cell carcinoma prior to definitive radiochemotherapy. In the PET images, the metabolic active volume (MTV) of the primary tumor was delineated with an adaptive threshold method. For the resulting ROIs, SUVmax and total lesion glycolysis (TLG = MTV × SUVmean) were computed. The blood SUV was determined by manually delineating the aorta in the low-dose CT. SUR values were computed as ratio of tumor SUV and blood SUV. Univariate Cox regression and Kaplan-Meier analysis with respect to overall survival (OS), distant-metastases-free survival (DM), and locoregional control (LRC) was performed. Additionally, a multivariate Cox regression including clinically relevant parameters was performed. RESULTS: Univariate Cox regression revealed MTV, TLG, and SURmax as significant prognostic factors for OS. MTV as well as TLG were significant prognostic factors for LRC while SURmax showed only a trend for significance. None of the PET parameters was prognostic for DM. In univariate analysis, SUVmax was not prognostic for any of the investigated clinical endpoints. In multivariate analysis (T-stage, N-stage, MTV, and SURmax), MTV was an independent prognostic factor for OS and showed a trend for significance for LRC. SURmax was not an independent predictor for OS or LRC. When including the PET parameters separately in multivariate analysis, MTV as well as SURmax were prognostic factors for OS indicating that SURmax is independent from the clinical parameters but not from MTV. In addition, MTV was an independent prognostic factor for LRC in this separate analysis. CONCLUSIONS: Our study revealed a clearly improved prognostic value of tumor SUR compared to tumor SUV and confirms our previously published findings regarding OS. Furthermore, SUR delivers prognostic information beyond that provided by the clinical parameters alone, but does not add prognostic information beyond that provided by MTV in this patient group. Therefore, our results suggest that pretherapeutic MTV is the parameter of choice for PET-based risk stratification in the considered setting but further investigations are necessary to demonstrate that this suggestion is correct.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Hofheinz F, Li Y, Steffen IG, et al. Confirmation of the prognostic value of pretherapeutic tumor SUR and MTV in patients with esophageal squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 2019. PMID: 30949816. doi:10.1007/s00259-019-04307-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。